Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial.

Nature medicine·2026
Same author

Advances and challenges of PET imaging in bladder cancer-An update and future trends.

Seminars in nuclear medicine·2026
Same author

SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST).

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Artificial intelligence-based lesion characterization and outcome prediction of prostate cancer on [<sup>18</sup>F]DCFPyL PSMA imaging.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Erratum: Phase II Study of <sup>177</sup>Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same journal

Cost-effectiveness of imaging modalities in coronary heart disease: A comprehensive review.

Seminars in nuclear medicine·2026
Same journal

Letter from the Editors.

Seminars in nuclear medicine·2026
Same journal

Expanding Horizons: The Role of Kaleidoscope and Relevant Images in Seminars in Nuclear Medicine.

Seminars in nuclear medicine·2026
Same journal

The diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma - A systematic review and meta-analysis.

Seminars in nuclear medicine·2026
Same journal

Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies.

Seminars in nuclear medicine·2026
Same journal

<sup>18</sup>F-FDG -PET/CT in cardiac sarcoidosis: Diagnosis, therapy monitoring, and future directions.

Seminars in nuclear medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

139

Update on PSMA-based Prostate Cancer Imaging.

Esther Mena1, Liza Lindenberg1, Peter L Choyke1

  • 1Molecular Imaging Program. National Cancer Institute, NIH, Bethesda, MD.

Seminars in Nuclear Medicine
|November 3, 2024
PubMed
Summary
This summary is machine-generated.

Prostate-specific membrane antigen (PSMA) PET imaging has transformed prostate cancer management. This advanced imaging offers superior detection of disease spread, becoming essential for personalized patient care and treatment planning.

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.4K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K

Related Experiment Videos

Last Updated: Jun 8, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

139
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.4K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiology

Background:

  • Prostate cancer (Pca) management has been significantly impacted by advancements in diagnostic imaging.
  • Prostate-specific membrane antigen (PSMA) PET imaging has emerged as a powerful tool in detecting prostate cancer.

Purpose of the Study:

  • To review the recent literature on PSMA PET imaging in prostate cancer.
  • To highlight the evolving role and clinical utility of PSMA PET in various stages of prostate cancer.

Main Methods:

  • Comprehensive literature review of recent studies on PSMA PET imaging for prostate cancer.
  • Analysis of diagnostic sensitivity and clinical utility across different disease stages.

Main Results:

  • PSMA PET imaging demonstrates higher diagnostic sensitivity for detecting extraprostatic disease.
  • Its clinical utility is increasing across all stages of prostate cancer, from initial diagnosis to recurrence.

Conclusions:

  • PSMA PET imaging is revolutionizing prostate cancer detection and management.
  • It is increasingly integrated into clinical guidelines, reducing reliance on conventional imaging methods.